Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 1997

View Archived Issues

Warner-Lambert develops antiretroviral agents

HOP-1 claimed by Signal for treatment of CNS disorders

Water-soluble camptothecin analogue reported by SKB

Allelix develops antiinflammatory peptides

GHRP mimetics reported by Pfizer for treatment of osteoporosis

Banyu prepares selective muscarinic antagonists with reduced side effects

Antiulcer agents from Otsuka

Japanese researchers isolate novel ACAT inhibitor

Dual COX-2/5-LO inhibitors reported by Searle

Pharmos AZT formulation provides improved CNS penetration

NIH offers licenses for anti-HIV fusion proteins

Invention related to melanoma antigens available for licensing

NIH seeks licensees for T-cell receptor technologies

Licenses offered for antibodies for treatment or diagnosis of breast cancer

Licensees sought for EGFR substrate

New SOD-CAT mimetic shows potential in situations of acute ischemia-reperfusion

Pivotal Integrilin study fully enrolled

Yuhan hepatoprotectant in phase II

Angiogenesis inhibitor induces dormancy in tumors

Positive results reported for Allervax Ragweed seasonal trial

New use for established antianginal agent

New use claimed for maprotiline

Collaborative project to focus on tailoring HIV treatment to reduce resistance

Lilly claims new indications for olanzapine

New ropinirole formulation described by SKB

Company Profile: Microcide Pharmaceuticals

TKT product advances toward the clinic

ImmunoGen to receive patent coverage for humanization technology

Genelabs granted patent coverage for gene-regulating drugs

MK-677 enhances GH activity in the elderly

Antisense compound targeting cholesterol reported

Preliminary analysis of pivotal trials on transdermal buspirone announced

FDA Cardiovascular and Renal Drugs Advisory Committee to meet February 27-28

Doxil superior to other treatments for first-line treatment of Kaposi's sarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...